Dupixent (dupilumab) Letter of Medical Necessity
Dupixent (dupilumab) prior authorization requests routinely require detailed documentation of severity scoring and prior topical/oral therapy. Missing severity metrics is the #1 cause of preventable denials.
FDA-Approved Indications
- ● atopic dermatitis
- ● asthma (eosinophilic or oral steroid-dependent)
- ● chronic rhinosinusitis with nasal polyps
- ● eosinophilic esophagitis
- ● prurigo nodularis
Why Dupixent Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Topical therapy trial inadequate or undocumented
- 2. EASI score, BSA, or IGA not on file
- 3. Eosinophil count missing for asthma indication
- 4. Age criteria not met
- 5. Specialty pharmacy enrollment incomplete
What to Include in a Dupixent Letter of Medical Necessity
Include objective severity scoring (EASI ≥16 or BSA ≥10% for AD, ACQ score and eosinophil count for asthma), documented failure of high-potency topical corticosteroids or calcineurin inhibitors, and impact on quality of life or work productivity.
Key clinical evidence to cite:
- ✓ SOLO 1, SOLO 2, CHRONOS, LIBERTY AD trials for atopic dermatitis
- ✓ QUEST and VENTURE trials for asthma
- ✓ SINUS-24 and SINUS-52 for CRSwNP
Relevant guidelines:
- 📖 AAD 2023 Atopic Dermatitis Guidelines
- 📖 GINA 2024 Asthma Strategy
- 📖 AAOA Nasal Polyp Position Statement
Dupixent Prior Authorization Criteria
Standard criteria across major US payers for Dupixent. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Topical therapy trial inadequate or undocumented
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Dupixent
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Dupixent Prior Authorization FAQ
Why was my Dupixent prior authorization denied?
The most common denial reasons for Dupixent are: Topical therapy trial inadequate or undocumented; EASI score, BSA, or IGA not on file; Eosinophil count missing for asthma indication; Age criteria not met; Specialty pharmacy enrollment incomplete.
What should a Dupixent Letter of Medical Necessity include?
Include objective severity scoring (EASI ≥16 or BSA ≥10% for AD, ACQ score and eosinophil count for asthma), documented failure of high-potency topical corticosteroids or calcineurin inhibitors, and impact on quality of life or work productivity.
Which payers cover Dupixent?
Dupixent is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem, Humana, though formulary tier and prior authorization criteria vary.